Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
23
every 2 weeks
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
RECRUITINGHokkaido University Hospital
Sapporo, Hokkaido, Japan
Objective response rate (ORR)
Time frame: up to 4.5 years
Objective response rate (ORR) (site investigator assesment)
Time frame: up to 4.5 years
Overall survival (OS)
Time frame: up to 4.5 years
Progression free survival (PFS)
Time frame: up to 4.5 years
Disease control rate (DCR)
Time frame: up to 4.5 years
Time to response (TTR)
Time frame: up to 4.5 years
Best overall response (BOR)
Time frame: up to 4.5 years
Percent change from baseline in the sum of diameters of target lesions
Time frame: up to 4.5 years
Best reduction percent change from baseline in the sum of diameters of target lesions
Time frame: up to 4.5 years
Incidence of Adverse Events [Safety]
Time frame: Up to 30 days after the last dose
North America Clinical Trial Support Desk
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hyogo Prefectural Kobe Children's Hospital
Kobe, Hyōgo, Japan
RECRUITINGOsaka City General Hospital
Osaka, Osaka, Japan
RECRUITINGNational Cancer Center Hospital
Chuo-ku, Tokyo, Japan
RECRUITINGChiba University Hospital
Chiba, Japan
RECRUITINGKyushu University Hospital
Fukuoka, Japan
NOT_YET_RECRUITINGFukushima Medical University Hospital
Fukushima, Japan
RECRUITINGHiroshima University Hospital
Hiroshima, Japan
RECRUITINGKanazawa University Hospital
Kanazawa, Japan
RECRUITING...and 4 more locations